	US 11,857,568 B2
	Treatment and prevention of Alzheimer's disease (AD)
Markus Mandler, Fort Lauderdale, FL (US); Achim Schneeberger, Fort Lauderdale, FL (US); Wolfgang Zauner, Fort Lauderdale, FL (US); Arne Von Bonin, Fort Lauderdale, FL (US); Frank Mattner, Fort Lauderdale, FL (US); and Walter Schmidt, Fort Lauderdale, FL (US)
Assigned to Advantage Therapeutics, Inc., Fort Lauderdale, FL (US)
Filed by Advantage Therapeutics, Inc., Fort Lauderdale, FL (US)
Filed on Jul. 8, 2021, as Appl. No. 17/370,615.
Application 17/370,615 is a continuation of application No. 15/307,246, granted, now 11,065,273, previously published as PCT/EP2015/059341, filed on Apr. 29, 2015.
Claims priority of application No. 14166355 (EP), filed on Apr. 29, 2014; and application No. 14166388 (EP), filed on Apr. 29, 2014.
Prior Publication US 2022/0000908 A1, Jan. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 33/06 (2006.01); A61K 33/08 (2006.01); A61K 33/42 (2006.01); A61K 45/06 (2006.01)

CPC A61K 33/06 (2013.01) [A61K 33/08 (2013.01); A61K 33/42 (2013.01); A61K 45/06 (2013.01)]

19 Claims

1. A method for treating mild cognitive impairment (MCI), comprising:

administering to a patient diagnosed with an MCI a pharmaceutical formulation comprising a sole active pharmaceutical ingredient, wherein the sole active pharmaceutical ingredient is an aluminum salt in an amount from about 1.0 mg to about 3.0 mg.